RWDD2B

Across TCGA pan-cancer cohorts, RWDD2B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RWDD2B data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RWDD2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RWDD2B expression acts as an unfavorable survival marker.

KIRC, MESO, and SKCM are the cancer types where RWDD2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.054	0.881	<.001	48	view →
MESO	OS	Median	III,IV	0.069	0.580	<.001	36	view →
SKCM	DFS	Median	All	0.192	0.738	<.001	24	view →
LUAD	OS	Median	All	0.141	0.788	<.001	18	view →
HNSC	OS	Median	III,IV	0.183	0.658	.009	15	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RWDD2B–KIRC (OS)

Open the KIRC breakdown →